‘Temporary’ stay not enough on abortion drug

Regarding the recent report on the Supreme Court’s temporary extension of access to Mifepristone, the stakes for women across the country could not be higher. With medication abortions now accounting for nearly two-thirds of all abortions in the U.S., any restriction on mail-order access or telehealth visits would be catastrophic.

For many women, especially in rural areas or states with strict bans, the ability to obtain this medication through the mail is not a convenience; it is their only path to safe health care. Restricting telehealth and requiring in-person visits creates an impossible barrier for those who cannot afford to travel hundreds of miles or take unpaid time off work.

The overturning of Roe v Wade has had a devastating effect on reproductive autonomy. In Roe v. Wade, the court originally held that the 14th Amendment due process clause protects a woman’s right to liberty, which includes the right to choose by challenging the FDA’s longstanding approval of Mifepristone. Opponents are attempting to dismantle the last remaining lifeline for this protected liberty in a post-Roe era. Before, women had more options for what was right for their bodies. Now, Mifepristone is often the only hope left in states where traditional clinical access has been abolished.

The Supreme Court must recognize that “temporary” stays are not enough. We need a definitive ruling that protects the modern medical standards that have made medication abortion a safe and accessible reality for millions of women over the last two decades.

Julie Brenner

Round Lake